Loading…
Loading…
SLN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for SLN and 80,000+ other tickers.
See exactly how SLN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SLN and 80,000+ other tickers.
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA)…
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silence Therapeutics plc (NasdaqGM: SLN) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of Silence will receive $20.00 in cash for each share of Silence that they own. KSF is seeking to determine whether this consideration and the process that led to.
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 20, 2026Insiders may stand to receive substantial financial benef
The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BALA CYNWYD, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 after agreeing to a $1.3 billion takeover by Merck KGaA, the German pharmaceutical and technology group. Merck will pay $20 in cash for each American depositary share (ADS), representing a 130% premium to Silence's closing price on October 16 and an 82% premium to its 30-day volume-weighted average price.